< Zurück zu den aktuellen Neuigkeiten & Events

Articles

UK – Billion pound support package for innovative firms hit by coronavirus

April 2020

The Chancellor has announced a new £1.25 billion coronavirus package to protect firms driving innovation in the UK.  The package includes a £500 million investment fund for high-growth companies impacted by the crisis, made up of funding from government and the private sector. SMEs focusing on research and development will also benefit from £750 million of grants and loans.

The announcement said the “targeted and tailored help aims to ensure firms in some of the most dynamic sectors of the UK economy – ranging from tech to life sciences – are protected through the crisis so they can continue to develop innovative new products and help power UK growth.”

The comprehensive package includes a new £500 million loan scheme for high-growth firms, called the Future Fund, and £750 million of targeted support for small and medium sized businesses focusing on research and development.

The scheme will be administered as follows:

“Delivered in partnership with the British Business Bank and launching in May, the fund will provide UK-based companies with between £125,000 and £5 million from the government, with private investors at least matching the government commitment. These loans will automatically convert into equity on the company’s next qualifying funding round, or at the end of the loan if they are not repaid. To be eligible, a business must be an unlisted UK registered company that has previously raised at least £250,000 in equity investment from third party investors in the last five years.

The £750 million of targeted support for the most R&D intensive small and medium size firms will be available through Innovate UK’s grants and loan scheme.

Innovate UK, the national innovation agency, will accelerate up to £200 million of grant and loan payments for its 2,500 existing Innovate UK customers on an opt-in basis. An extra £550 million will also be made available to increase support for existing customers and £175,000 of support will be offered to around 1,200 firms not currently in receipt of Innovate UK funding. The first payments will be made by mid-May.”

This update was prepared by HGF Partner Hsu Min Chung. If you would like further advice on this please contact Hsu Min.  Alternatively, you can contact your usual HGF representative or visit our Contact page to get in touch with your nearest HGF office.

Aktuelle Neuigkeiten

Event - 7. January 2026

HGF Brand & Design Conference 2026

Join us on 3rd February 2026 for HGF’s Brand & Design Conference, the must attend event for in-house legal teams, brand leaders, creatives, and innovators shaping the future of IP. …

Veranstaltungsdetails

Empowered, Not Replaced: The Risks and Rewards of Using AI Tools in Patent Prosecution

With the rapid rise of AI and extreme hype around generative AI tools in the workplace, patent firms around the world have had to seriously consider to what extent they …

Weiterlesen

EU Agrees on NGT Plant Regulation: What It Means for Patents and Licensing

The European Parliament and Council have reached a provisional agreement for plants developed using New Genomic Techniques (NGTs) – below we summarise the main points and set out the requirements …

Weiterlesen

When Retail Branding Meets Politics

(Inter IKEA Systems v Algemeen Vlaams Belang (Case C‑298/23) In November 2022, the Flemish political party Vlaams Belang presented its “IKEA-PLAN – Immigratie Kan Echt Anders” (“Immigration Really Can Be Different”). …

Weiterlesen

Büro geschlossen – Dezember 2025 / Januar 2026

HGF Büro geschlossen – Dezember 2025 / Januar 2026   UK Donnerstag, 25. und Freitag, 26. Dezember 2025 GESCHLOSSEN Donnerstag, 1. Januar 2026* GESCHLOSSEN * Freitag, 2. Januar 2026 – …

Weiterlesen

Oft kopiert, nie erreicht: Wann werden Alltagsgegenstände zum Gegenstand des Urheberrechts?

Die Grenze zwischen „reinen“ Kunstwerken und bloßen Gebrauchsgegenständen – Können ikonische, aber alltägliche Produkte urheberrechtlich geschützt werden? Die obige Frage wurde vom Generalanwalt in den verbundenen Rechtssachen C‑580/23 und C‑795/23 …

Weiterlesen

T 0883/23: Dosierungsansprüche und ihr Anspruch auf Priorität, wenn in der Prioritätsanmeldung nur das Protokoll der klinischen Studie offengelegt wurde

In einer kürzlich ergangenen Entscheidung der Beschwerdekammer (BoA) des EPA entschied die BoA, dass Ansprüche, die auf eine Kombination von pharmazeutischen Wirkstoffen (APIs) in bestimmten Dosen gerichtet sind, keinen Anspruch …

Weiterlesen

Das Ende des Brexit-Überhangs für Marken: Überprüfung, Neuanmeldung und Widerruf.

Am 31. Dezember 2025 sind fünf Jahre seit dem Ende der Brexit-Übergangsperiode am 31. Dezember 2020 vergangen. Warum ist das relevant? Für im Vereinigten Königreich geklonte Markenregistrierungen, die infolge des …

Weiterlesen